<DOC>
	<DOCNO>NCT01781546</DOCNO>
	<brief_summary>The purpose study compare DEB BMS CAD patient high risk bleeding use DES therefore avoid . Our hypothesis PCI DEB non-inferior BMS treatment stable CAD ACS ( UAP NSTEMI ) patient high risk bleeding .</brief_summary>
	<brief_title>Drug-Eluting Balloon Stable Unstable Angina</brief_title>
	<detailed_description>Stenting reduce need revascularization procedure stable CAD ACS compare POBA . The use stent favor stable CAD ACS accord present ESC guideline . However , especially patient warfarin patient high bleed risk , stenting ( use DES particular ) recommend longer DAPT require . In patient , BMS may use shorten duration DAPT . However , problem associate treatment use BMS . First , considerable high rate restenosis associate stenting BMS . Furthermore , stenting may complicate `` no-reflow '' phenomenon , coronary dissection closure side branch treatment bifurcation lesion . Implantation stent also expose patient stent thrombosis . In contrast , problem may avoid use DEB provisional BMS strategy . The use DEB already establish treatment ISR . Despite lack data RCTs , DEB already widely use variety clinical situation stenting desirable . These situation include example anticoagulation treatment , high bleeding risk , poor compliance regard medication , small vessel , bifurcation lesion , long and/or calcified lesion , case mark variation vessel reference caliber , long lesion patient ACS . The all-comer registry data promise hypothesis generate . Thus , would important ethical test efficacy DEB wider patient population randomize control study . Our hypothesis DEB non-inferior BMS treatment stable CAD ACS ( UAP NSTEMI ) patient anticoagulation medication otherwise high bleeding risk . Our study shed light use DEB PCI challenge patient population . In previous study , BMS routinely add DEB treatment . This strategy seem yield benefit contrast cause increase risk restenosis compare DEB strategy provisional stenting . Finally , current data use DEB patient ACS scarce study give significant information also important issue .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<criteria>Age ≥ 18 year Informed write consent At least one follow 1 . Patient use oral anticoagulation ( warfarin , dabigatran rivaroxaban ) 2 . Anemia ( hemoglobin threshold : &lt; 117g/l woman &lt; 134 g/l men ) thrombocytopenia ( &lt; 100 ) detect &lt; 6 month prior PCI 3 . Active malign disease ( metastatic cancer ongoing radio chemotherapy ) 4 . Prior intracerebral hemorrhage ischemic stroke 5 . Severe kidney liver dysfunction ( eGFR &lt; 30ml/kg/min , liver cirrhosis , BIL &gt; 2x threshold ALAT &gt; 3x threshold ) 6 . Elective surgery plan &lt; 12 month PCI 7 . General frailty e.g . long corticosteroid treatment generalize cachexia ( BMI &lt; 20 kg/m2 ) 8 . Age ≥ 80 year 9 . Inability suspect inability use DAPT 12 month Either follow : 1 . Stable angina dyspnea coronary narrow cause myocardial ischemia detect angiogram . Ischemia document pressure wire measurement ( FFR ) noninvasive test stress ECG test perfusion image 2 . ACS ( UAP NSTEMI ) : symptom heart ischemia ≥ 20 minute ≥ 0,5mm STdepression transient STelevation Twave inversion least two adjacent lead and/or high sensitivity troponin ( hstnt ) rise least one unit 99. percentile least 50 % rise hstnt two sample take 3 hour apart ≥1 de novo lesion native coronary artery bypass vein graft Reference diameter vessel 2,254,0mm Lesion lesion suitable PCI Inability give write consent STEMI Reference diameter vessel &lt; 2,25mm &gt; 4,0mm Bifurcation lesion require stenting side branch Dissection affect flow ( TIMI &lt; 3 ) significant recoil ( &gt; 30 % main branch , &gt; 50 % side branch ) predilatation Instent restenosis Life expectancy &lt; 12 month Cardiogenic shock arrival coronary angiography Uncertainty neurological recovery e.g . resuscitation Unprotected left main ( LM ) lesion Chronic total occlusion ( CTO )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>drug elute balloon</keyword>
	<keyword>bare metal stent</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>DEB</keyword>
	<keyword>BMS</keyword>
</DOC>